Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07197697 | Oct 2025 → Nov 2027 expected | breast cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07197697 ↗ |
| Known as | QL1706 | “Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy” NCT07197697 ↗ |
| Route | Intravenous | “administered intravenously” NCT07197697 ↗ |